Viral pneumonias: Epidemic respiratory viruses

Postgraduate Medicine

Volumn 107, Issue 3, 2000, Pages 41-52

  Chien, Jason W ^a   Johnson, John L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTIPYRETIC AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ZANAMIVIR;

AGING; ANOREXIA; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CONFUSION; COUGHING; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HALLUCINATION; HEADACHE; HUMAN; IMMUNE DEFICIENCY; INFLUENZA VIRUS; INSOMNIA; MALAISE; MYALGIA; NAUSEA; NERVOUSNESS; PARAINFLUENZA VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SORE THROAT; VERTIGO; VIRUS ISOLATION; VIRUS PNEUMONIA;

EID: 0034061273     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.03.941     Document Type: Article

References (15)

1. Balfour HH. Drug therapy: antiviral drugs. N Engl J Med 1999:1255-68
2. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-26
3. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275:295-9
4. Hayden FG, Osterhaus AD, Treanor JJ, et al, for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80
5. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization: respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161:402-6
6. Mlinaric-Galinovic G, Falsey AR, Walsh EE. Respiratory syncytial virus infection in the elderly. Eur J Clin Microbiol Infect Dis 1996;15:777-81
7. Yang E, Rubin BK. "Childhood" viruses as a cause of pneumonia in adults. Semin Respir Infect 1995;10:232-43
8. Dowell SF, Anderson LJ, Gary HE Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996;174:456-62
9. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165: 987-93
10. Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect 1995;10:224-31
11. Falsey AR, McCann RM, Hall WJ, et al. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. J Am Geriatr Soc 1996;44: 71-3
12. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996;97:137-40
13. Wandstrat TL. Respiratory syncytial virus immune globulin intravenous. Ann Pharmacother 1997;31:83-8
14. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7
15. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-6